Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Aug;41(8):1668–1672. doi: 10.1128/aac.41.8.1668

Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.

J A Zix 1, H F Geerdes-Fenge 1, M Rau 1, J Vöckler 1, K Borner 1, P Koeppe 1, H Lode 1
PMCID: PMC163982  PMID: 9257738

Abstract

In an open, randomized, triple crossover study, the effects of cisapride and sucralfate on the pharmacokinetics of sparfloxacin were assessed. Fifteen healthy volunteers received 400 mg of sparfloxacin as a single oral dose on day 0. In a random order, concomitant doses of 10 mg of cisapride three times daily from day -2 to day 2 and 1 g of sucralfate four times daily from day -2 to day 0 were administered. Sparfloxacin concentrations were measured by bioassay and high-performance liquid chromatography. Pharmacokinetic parameters for sparfloxacin alone were as follows (mean +/- standard deviation): maximum concentration of drug in serum (C(max)), 1.27 +/- 0.39 microg/ml; time to C(max) (T(max)), 4.1 +/- 1.9 h; area under the concentration-time curve (AUC), 35.0 +/- 9.7 microg x h/ml; mean residence time, 28.5 +/- 5.7 h; half-life (t1/2), 20 +/- 4 h; urinary recovery (UR x f), 11.0% +/- 2.7%; and metabolite-sparfloxacin ratio in urine, 2.6. For the cisapride group there was a significant decrease in the sparfloxacin T(max) (1.9 +/- 2.1 h) and a significant increase in C(max) (1.74 +/- 0.73 microg/ml). The QTc interval for patients receiving sparfloxacin and cisapride was prolonged by 7.7% compared to the QTc interval during medication-free periods. Significant differences in the values for the group receiving sucralfate compared to the values for the group receiving sparfloxacin alone were found: C(max), 0.77 +/- 0.31 microg/ml; AUC, 18.6 +/- 5.8 microg x h/ml; t1/2, 26 +/- 10 h; and UR x f, 5.8 +/- 1.8%. Concomitant adminstration of cisapride accelerates the absorption and increases the peak concentration of sparfloxacin without having a significant effect on the extent of bioavailability. Coadministration of sucralfate leads to a 44% decrease in the bioavailability of sparfloxacin.

Full Text

The Full Text of this article is available as a PDF (233.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allain P., Mauras Y., Krari N., Duchier J., Cournot A., Larcheveque J. Plasma and urine aluminium concentrations in healthy subjects after administration of sucralfate. Br J Clin Pharmacol. 1990 Apr;29(4):391–395. doi: 10.1111/j.1365-2125.1990.tb03655.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Averdunk R., Borner K. Korrelation der Thromboplastinzeiten bei Dicumarol-behandelten Patienten unter Verwendung verschiedener Thrombokinase-Präparate. Z Klin Chem Klin Biochem. 1970 May;8(3):263–268. [PubMed] [Google Scholar]
  3. Barry A. L., Fuchs P. C. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin. Antimicrob Agents Chemother. 1991 May;35(5):955–960. doi: 10.1128/aac.35.5.955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bateman D. N. The action of cisapride on gastric emptying and the pharmacodynamics and pharmacokinetics of oral diazepam. Eur J Clin Pharmacol. 1986;30(2):205–208. doi: 10.1007/BF00614304. [DOI] [PubMed] [Google Scholar]
  5. Bodey G. P., Rodriguez V., Hart J., Freireich E. J. Therapy of acute leukemia with the combination of cytosine arabinoside (NSC-63878) and cyclophosphamide (NSC-26271). Cancer Chemother Rep. 1970 Aug;54(4):255–262. [PubMed] [Google Scholar]
  6. Borner K., Borner E., Lode H. Determination of sparfloxacin in serum and urine by high-performance liquid chromatography. J Chromatogr. 1992 Sep 2;579(2):285–289. doi: 10.1016/0378-4347(92)80393-5. [DOI] [PubMed] [Google Scholar]
  7. Bran S., Murray W. A., Hirsch I. B., Palmer J. P. Long QT syndrome during high-dose cisapride. Arch Intern Med. 1995 Apr 10;155(7):765–768. [PubMed] [Google Scholar]
  8. Deppermann K. M., Lode H. Fluoroquinolones: interaction profile during enteral absorption. Drugs. 1993;45 (Suppl 3):65–72. doi: 10.2165/00003495-199300453-00013. [DOI] [PubMed] [Google Scholar]
  9. Fisher R. S. Sucralfate: a review of drug tolerance and safety. J Clin Gastroenterol. 1981;3(Suppl 2):181–184. [PubMed] [Google Scholar]
  10. Garrelts J. C., Godley P. J., Peterie J. D., Gerlach E. H., Yakshe C. C. Sucralfate significantly reduces ciprofloxacin concentrations in serum. Antimicrob Agents Chemother. 1990 May;34(5):931–933. doi: 10.1128/aac.34.5.931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hollander D., Tarnawski A. The protective and therapeutic mechanisms of sucralfate. Scand J Gastroenterol Suppl. 1990;173:1–5. doi: 10.3109/00365529009091917. [DOI] [PubMed] [Google Scholar]
  12. Jaillon P., Morganroth J., Brumpt I., Talbot G. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group. J Antimicrob Chemother. 1996 May;37 (Suppl A):161–167. doi: 10.1093/jac/37.suppl_a.161. [DOI] [PubMed] [Google Scholar]
  13. Johnson J. H., Cooper M. A., Andrews J. M., Wise R. Pharmacokinetics and inflammatory fluid penetration of sparfloxacin. Antimicrob Agents Chemother. 1992 Nov;36(11):2444–2446. doi: 10.1128/aac.36.11.2444. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kirch W., Janisch H. D., Santos S. R., Duhrsen U., Dylewicz P., Ohnhaus E. E. Effect of cisapride and metoclopramide on digoxin bioavailability. Eur J Drug Metab Pharmacokinet. 1986 Oct-Dec;11(4):249–250. doi: 10.1007/BF03189108. [DOI] [PubMed] [Google Scholar]
  15. Kojima T., Inoue M., Mitsuhashi S. In vitro activity of AT-4140 against clinical bacterial isolates. Antimicrob Agents Chemother. 1989 Nov;33(11):1980–1988. doi: 10.1128/aac.33.11.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lewin M. B., Bryant R. M., Fenrich A. L., Grifka R. G. Cisapride-induced long QT interval. J Pediatr. 1996 Feb;128(2):279–281. doi: 10.1016/s0022-3476(96)70409-2. [DOI] [PubMed] [Google Scholar]
  17. Madsen J. L. Effects of cisapride on gastrointestinal transit in healthy humans. Dig Dis Sci. 1990 Dec;35(12):1500–1504. doi: 10.1007/BF01540568. [DOI] [PubMed] [Google Scholar]
  18. Montay G., Bruno R., Vergniol J. C., Ebmeier M., Le Roux Y., Guimart C., Frydman A., Chassard D., Thebault J. J. Pharmacokinetics of sparfloxacin in humans after single oral administration at doses of 200, 400, 600, and 800 mg. J Clin Pharmacol. 1994 Nov;34(11):1071–1076. doi: 10.1002/j.1552-4604.1994.tb01983.x. [DOI] [PubMed] [Google Scholar]
  19. Nakamura S., Minami A., Nakata K., Kurobe N., Kouno K., Sakaguchi Y., Kashimoto S., Yoshida H., Kojima T., Ohue T. In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone. Antimicrob Agents Chemother. 1989 Aug;33(8):1167–1173. doi: 10.1128/aac.33.8.1167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Nix D. E., Watson W. A., Handy L., Frost R. W., Rescott D. L., Goldstein H. R. The effect of sucralfate pretreatment on the pharmacokinetics of ciprofloxacin. Pharmacotherapy. 1989;9(6):377–380. doi: 10.1002/j.1875-9114.1989.tb04152.x. [DOI] [PubMed] [Google Scholar]
  21. Parpia S. H., Nix D. E., Hejmanowski L. G., Goldstein H. R., Wilton J. H., Schentag J. J. Sucralfate reduces the gastrointestinal absorption of norfloxacin. Antimicrob Agents Chemother. 1989 Jan;33(1):99–102. doi: 10.1128/aac.33.1.99. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Peck C. C., Sheiner L. B., Nichols A. I. The problem of choosing weights in nonlinear regression analysis of pharmacokinetic data. Drug Metab Rev. 1984;15(1-2):133–148. doi: 10.3109/03602538409015060. [DOI] [PubMed] [Google Scholar]
  23. Qadri S. M., Ueno Y., Burns J. J., Almodovar E., Rabea N. In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone. Chemotherapy. 1992;38(2):99–106. doi: 10.1159/000238948. [DOI] [PubMed] [Google Scholar]
  24. Shimada J., Nogita T., Ishibashi Y. Clinical pharmacokinetics of sparfloxacin. Clin Pharmacokinet. 1993 Nov;25(5):358–369. doi: 10.2165/00003088-199325050-00002. [DOI] [PubMed] [Google Scholar]
  25. Tryba M. Stress bleeding prophylaxis with sucralfate. Pathophysiologic basis and clinical use. Scand J Gastroenterol Suppl. 1990;173:22–33. doi: 10.3109/00365529009091920. [DOI] [PubMed] [Google Scholar]
  26. Visser M. R., Rozenberg-Arska M., Beumer H., Hoepelman I. M., Verhoef J. Comparative in vitro antibacterial activity of sparfloxacin (AT-4140; RP 64206), a new quinolone. Antimicrob Agents Chemother. 1991 May;35(5):858–868. doi: 10.1128/aac.35.5.858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Wiseman L. R., Faulds D. Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs. 1994 Jan;47(1):116–152. doi: 10.2165/00003495-199447010-00008. [DOI] [PubMed] [Google Scholar]
  28. Wysowski D. K., Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med. 1996 Jul 25;335(4):290–291. doi: 10.1056/NEJM199607253350416. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES